Michael J. Pishvaian, MD, PhD, discusses the key takeaway from his presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology on the role of genetic testing in patients with pancreatic cancer.
Michael Pishvaian, MD, PhD
Advertisement
Articles by Michael Pishvaian, MD, PhD
Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study investigating entrectinib in patients with metastatic pancreatic cancer who harbor <em>NTRK</em> and <em>ROS1</em> fusions.
Advertisement
Latest Updated Articles
Genetic Testing Should Be Considered for All Patients With Pancreatic CancerPublished: October 5th 2020 | Updated:
Clinical Benefit of Entrectinib for Patients With Metastatic Pancreatic CancerPublished: January 26th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
